Christoph Bruening
Corporate Officer/Principal presso Value Relations GmbH
Provenienza dei contatti di primo grado di Christoph Bruening
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY.
15
| Extinct | Pharmaceuticals: Major | 15 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Christoph Bruening tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| SYNERGY PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder Chief Executive Officer Founder Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| OKYO PHARMA LIMITED | Biotechnology | Director/Board Member Chairman Chief Executive Officer Director/Board Member Director/Board Member | |
| HEPION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman Founder Chief Executive Officer Director of Finance/CFO | |
| ACTAVIA LIFE SCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
| CARDIFF ONCOLOGY, INC. | Medical Specialties | Director/Board Member Founder Director/Board Member Director/Board Member | |
Tiziana Life Sciences Ltd. (United Kingdom)
 Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Chief Executive Officer Chief Executive Officer | |
| TIZIANA LIFE SCIENCES LTD | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Chief Executive Officer | |
| ACCUSTEM SCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member | |
| SIGA TECHNOLOGIES, INC. | Pharmaceuticals: Major | Chairman President Director/Board Member | |
| Lev Development Corp. | Chairman Chief Executive Officer | ||
Arna Therapeutics Ltd.
 Arna Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Arna Therapeutics Ltd. is a British biotechnology company that focuses on research and experimental development. The private company was founded by Gabriele Marco Antonio Cerrone. | Miscellaneous Commercial Services | Director/Board Member Founder | |
FermaVir Pharmaceuticals LLC
 FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Pharmaceuticals: Major | Director/Board Member Founder | |
Prism Venture Management LLC
 Prism Venture Management LLC Investment ManagersFinance Prism Venture Management LLC (Prism Venture Management) is a venture capital firm founded in 1996 by Bob C. Fleming and John L. Brooks. The firm is headquartered in Needham, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
Lev Pharmaceuticals, Inc.
 Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company was founded on July 21, 2003 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chairman President | |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Medical Specialties | Director/Board Member Director/Board Member | |
Tapestry Pharmaceuticals, Inc.
 Tapestry Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tapestry Pharmaceuticals, Inc. develops, manufactures, and markets an anti-cancer pharmaceutical called Paclitaxel. It focuses on the development of proprietary therapies for the treatment of cancer, new products and technologies may involve the examination of individual molecules and classes of compounds. The company was founded in 1991 and is headquartered in Ankeny, IA. | Pharmaceuticals: Major | Director/Board Member President | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal Director/Board Member | |
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Masters Business Admin | |
| PREMIER VETERINARY GROUP PLC | Agricultural Commodities/Milling | Chairman | |
| University of London | College/University | Undergraduate Degree | |
| ANATARA LIFESCIENCES LTD | Pharmaceuticals: Major | Director/Board Member | |
| University of Wisconsin | College/University | Doctorate Degree | |
| University of Oxford | College/University | Corporate Officer/Principal | |
| Synergy DE | Chairman | ||
| E-THERAPEUTICS PLC | Biotechnology | Chairman | |
| MONSANTO | Wholesale Distributors | Chief Tech/Sci/R&D Officer | |
| G.D. Searle LLC | Corporate Officer/Principal | ||
| IMMURON LIMITED | Pharmaceuticals: Major | Chief Executive Officer | |
| VIRPAX PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| University of Missouri-St. Louis | College/University | Undergraduate Degree | |
| KAZIA THERAPEUTICS LIMITED | Pharmaceuticals: Major | Chief Executive Officer | |
Lonza Biologics Plc
 Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
The Institute of Directors (United Kingdom)
 The Institute of Directors (United Kingdom) Miscellaneous Commercial ServicesCommercial Services The Institute of Directors (United Kingdom) is a community of passionate UK business leaders. The non-profit company is based in Birmingham, UK, and has subsidiaries in the United Kingdom. The British company provides professional training opportunities and access to essential help and resources for its members. The CEO of the company is Stephen Martin. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| BIVICTRIX THERAPEUTICS PLC | Pharmaceuticals: Major | Chairman | |
| RENEURON GROUP PLC | Pharmaceuticals: Major | Chairman | |
| PALA PHAR | Pharmaceuticals: Major | Director/Board Member | |
Sandoz AG
 Sandoz AG Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland. | Pharmaceuticals: Generic | Chief Executive Officer | |
| Royal Holloway University of London | College/University | Corporate Officer/Principal | |
Redx Oncology Ltd.
 Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | Pharmaceuticals: Major | Director/Board Member | |
| REDX PHARMA PLC | Pharmaceuticals: Major | Chief Executive Officer |
Statistiche
Distribuzione geografica
| Stati Uniti | 28 |
| Regno Unito | 17 |
| Australia | 5 |
| Bermuda | 2 |
| Canada | 2 |
Settori
| Health Technology | 31 |
| Consumer Services | 8 |
| Commercial Services | 5 |
| Distribution Services | 3 |
| Retail Trade | 2 |
Posizioni
| Director/Board Member | 95 |
| Chairman | 36 |
| Corporate Officer/Principal | 36 |
| Chief Tech/Sci/R&D Officer | 26 |
| Independent Dir/Board Member | 23 |
Contatti più connessi
| Insiders | |
|---|---|
| Iain Ross | 41 |
| Gabriele Cerrone | 22 |
| Stephen K. Carter | 20 |
| John Brancaccio | 18 |
| Riccardo Dalla-Favera | 18 |
| Gary Jacob | 16 |
| Donald Picker | 16 |
| Kunwar Shailubhai | 14 |
| Joshua D. Schein | 12 |
| Bernard Denoyer | 11 |
| Judson A. Cooper | 10 |
| Robert C. Shepard | 9 |
| Craig C. Talluto | 4 |
| Randall K. Johnson | 3 |
| Pamela A. Harris | 2 |
- Borsa valori
- Insiders
- Christoph Bruening
- Connessioni Società
